Using GLP-1 Drugs for Weight Loss Before Pregnancy: What We Know So Far

GLP-1 drugs are increasingly used for pre-conception weight management in women with obesity, despite limited safety data for this context.

Price, Sarah A L et al.·Archives of gynecology and obstetrics·2025·low-moderateNarrative Review
RPEP-13110Narrative Reviewlow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Narrative Review
Evidence
low-moderate
Sample
N=N/A (review)
Participants
Women of reproductive age with obesity considering pregnancy

What This Study Found

GLP-1 drugs are being used off-label for pre-conception weight management, but safety data for this specific context remains limited.

Key Numbers

No specific efficacy data from pre-conception trials; reviews observational and animal safety data.

How They Did This

Narrative review of PubMed, Medline, and Embase literature on GLP-1 RA use before and during pregnancy.

Why This Research Matters

With millions of reproductive-age women now taking GLP-1 drugs, understanding pre-conception implications is urgent.

The Bigger Picture

This represents a growing tension between the proven benefits of pre-conception weight loss and the unknown risks of GLP-1 drug exposure near conception.

What This Study Doesn't Tell Us

Narrative review — evidence base is sparse. Most pregnancy exposure data comes from inadvertent rather than planned use.

Questions This Raises

  • ?How long before conception should GLP-1 drugs be stopped?
  • ?Does pre-conception GLP-1 use improve pregnancy outcomes despite drug discontinuation?

Trust & Context

Key Stat:
Off-label use GLP-1 drugs increasingly used pre-conception for weight management despite limited pregnancy safety guidelines
Evidence Grade:
Narrative review — summarizes limited available evidence. No randomized trials of pre-conception GLP-1 use exist.
Study Age:
Published in 2025, addressing a rapidly emerging clinical question.
Original Title:
Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.
Published In:
Archives of gynecology and obstetrics, 311(5), 1241-1247 (2025)
Database ID:
RPEP-13110

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research without a strict systematic method.

What do these levels mean? →

Frequently Asked Questions

Can I take a GLP-1 drug before getting pregnant?

Some women use them for pre-conception weight loss, but safety data is limited. Current guidance recommends stopping before conception.

How long before pregnancy should I stop GLP-1 medication?

Specific washout recommendations vary by drug. Discuss timing with your OB-GYN or reproductive endocrinologist well before trying to conceive.

Read More on RethinkPeptides

Cite This Study

RPEP-13110·https://rethinkpeptides.com/research/RPEP-13110

APA

Price, Sarah A L; Nankervis, Alison. (2025). Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.. Archives of gynecology and obstetrics, 311(5), 1241-1247. https://doi.org/10.1007/s00404-024-07849-9

MLA

Price, Sarah A L, et al. "Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review.." Archives of gynecology and obstetrics, 2025. https://doi.org/10.1007/s00404-024-07849-9

RethinkPeptides

RethinkPeptides Research Database. "Considering the use of GLP-1 receptor agonists in women with..." RPEP-13110. Retrieved from https://rethinkpeptides.com/research/price-2025-considering-the-use-of

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.